There’s a new article in the Acta Materia Medica journal about prostate cancer (PrCa), the most common type of urogenital cancer in men. This disease happens when cells in the prostate grow uncontrollably, causing the gland to enlarge. The biggest threat from PrCa is its ability to spread, or metastasize, often affecting bones and other organs. This spread is a major cause of death from the disease.
Several factors contribute to the growth of PrCa. These include genetic changes, increased activity of androgen receptors, and the presence of specific gene variants. Currently, androgen deprivation therapy is the primary treatment for early-stage PrCa. However, this treatment often becomes less effective, with many cases progressing to castration-resistant PrCa (CRPC), which poses a significant challenge for treatment.
This review looks at important biomarkers for PrCa and discusses the latest treatment strategies for CRPC, especially focusing on a new method called proteolysis-targeting chimera (PROTAC) technology. PROTAC offers a fresh approach to breaking down proteins that contribute to drug resistance in CRPC, showing promise as a potential solution in the fight against this challenging cancer.
Source:
Journal reference:
Wang, Z., et al. (2025) PROTAC technology for prostate cancer treatment. Acta Materia Medica. doi.org/10.15212/AMM-2024-0075.
Source link
Cancer, Cancer Treatment, Prostate, Prostate Cancer, Technology, Androgen, Receptor
